CytoDyn to Present at the LD Micro Invitational XVI
Rhea-AI Summary
CytoDyn (OTCQB: CYDY), a clinical-stage oncology company advancing leronlimab, announced that CFO Robert E. Hoffman will present a corporate overview at the LD Micro Invitational XVI in Los Angeles.
The presentation is scheduled for May 18, 2026 at 10 a.m. PDT and will be available via webcast.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
CFO Robert E. Hoffman to deliver company presentation on May 18 at 10 a.m. PT
VANCOUVER, Washington, May 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (“mTNBC”) and colorectal cancer (“CRC”), today announced that CFO Robert E. Hoffman will present a corporate overview at the LD Micro Invitational XVI, taking place May 17-19, 2026, at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
Presentation Date: Monday, May 18, 2026
Time: 10 a.m. PDT
Link to view presentation: Webcast Link - LD Micro Invitational XVI.
Mr. Hoffman will be available for one-on-one meetings with conference attendees. To request a meeting to discuss the Company’s current development strategy and upcoming milestones, please contact ir@cytodyn.com.
About LD Micro
LD Micro is dedicated to being the definitive resource in the small-cap space. From its industry-recognized index and robust data to hosting some of the most influential events each year, LD Micro’s mission is to provide unparalleled access and insight for those seeking the next generation of great companies.
To learn more about LD Micro, visit http://www.ldmicro.com.
About CytoDyn
CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.
For more information, please visit www.cytodyn.com and follow us on LinkedIn.
Note Regarding Forward-Looking Statements
This news release may contain forward-looking statements relating to, among other things, the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2025, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.
Corporate Contact
CytoDyn Inc.
ir@cytodyn.com
Media Contacts
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
CytoDyn@russopartnersllc.com
